Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 3500
- Registration Number
- NCT06134362
- Locations
- πΉπ
GSK Investigational Site, Pathum Wan, Thailand
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
Phase 2
Suspended
- Conditions
- HIV Infections
- Interventions
- Drug: VH3739937Drug: Placebo
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 26
- Registration Number
- NCT06061081
- Locations
- πͺπΈ
GSK Investigational Site, Vitoria, Spain
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
Phase 2
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- Drug: VH4004280Drug: VH4004280 Matching PlaceboDrug: VH4011499Drug: VH4011499 Matching Placebo
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 43
- Registration Number
- NCT06039579
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 48
- Registration Number
- NCT06033547
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
Phase 1
Recruiting
- Conditions
- HIV Infections
- Interventions
- Drug: VH4004280Drug: VH4011499Drug: Placebo
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 160
- Registration Number
- NCT06012136
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
Phase 2
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 128
- Registration Number
- NCT05996471
- Locations
- π΅π·
GSK Investigational Site, San Juan, Puerto Rico
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
Phase 3
Recruiting
- Conditions
- HIVHIV Infections
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 412
- Registration Number
- NCT05979311
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
Phase 3
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 171
- Registration Number
- NCT05917509
- Locations
- πͺπΈ
GSK Investigational Site, Sevilla, Spain
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
Phase 3
Active, not recruiting
- Conditions
- HIVHIV Infections
- Interventions
- Drug: DTG/3TC
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 206
- Registration Number
- NCT05911360
- Locations
- π¬π§
GSK Investigational Site, Manchester, United Kingdom
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 118
- Registration Number
- NCT05896761
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
Β© Copyright 2025. All Rights Reserved by MedPath